Home LiteratureArticle Details
PMID: 18039136 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Pancreatic cancer.

Annual review of pathology ·Vol. 3 ·2008-00-00 ·Pages 157-88

Maitra A, Hruban RH

Abstract

The past two decades have witnessed an explosion in our understanding of pancreatic cancer, and it is now clear that pancreatic cancer is a disease of inherited (germ-line) and somatic gene mutations. The genes mutated in pancreatic cancer include KRAS2, p16/CDKN2A, TP53, and SMAD4/DPC4, and these are accompanied by a substantial compendium of genomic and transcriptomic alterations that facilitate cell cycle deregulation, cell survival, invasion, and metastases. Pancreatic cancers do not arise de novo, and three distinct precursor lesions have been identified. Experimental models of pancreatic cancer have been developed in genetically engineered mice, which recapitulate the multistep progression of the cognate human disease. Although the putative cell of origin for pancreatic cancer remains elusive, minor populations of cells with stem-like properties have been identified that appear responsible for tumor initiation, metastases, and resistance of pancreatic cancer to conventional therapies.

MeSH Terms
Animals Disease Models, Animal Humans Mice Pancreatic Neoplasms/genetics,pathology
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Maitra Anirban
Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. amaitra1@jhmi.edu
Hruban Ralph H
References (186)
186 references, click to expand
  1. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma.
    Oncogene. 2007 Jun 28;26(30):4442-52 PMID: 17237814
  2. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
    Nature. 2006 Dec 7;444(7120):756-60 PMID: 17051156
  3. Origin of exocrine pancreatic cells from nestin-positive precursors in developing mouse pancreas.
    Mech Dev. 2004 Jan;121(1):15-25 PMID: 14706696
  4. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.
    Gastroenterology. 2002 Jul;123(1):365-72 PMID: 12105864
  5. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.
    Cancer Res. 1994 Jun 1;54(11):3025-33 PMID: 8187092
  6. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas.
    Am J Pathol. 2002 May;160(5):1745-54 PMID: 12000726
  7. MAP2K4/MKK4 expression in pancreatic cancer: genetic validation of immunohistochemistry and relationship to disease course.
    Clin Cancer Res. 2004 Dec 15;10(24):8516-20 PMID: 15623633
  8. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas.
    Am J Surg Pathol. 1998 Feb;22(2):163-9 PMID: 9500216
  9. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas.
    Am J Pathol. 2000 Sep;157(3):755-61 PMID: 10980115
  10. Notch signaling in leukemia.
    Annu Rev Pathol. 2008;3:587-613 PMID: 18039126
  11. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy.
    Cancer Biol Ther. 2005 Jan;4(1):83-6 PMID: 15662124
  12. Integrating genetic approaches into the discovery of anticancer drugs.
    Science. 1997 Nov 7;278(5340):1064-8 PMID: 9353181
  13. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers.
    Am J Pathol. 1999 Jun;154(6):1835-40 PMID: 10362809
  14. Cancer. Addiction to oncogenes--the Achilles heal of cancer.
    Science. 2002 Jul 5;297(5578):63-4 PMID: 12098689
  15. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships.
    Cancer Genet Cytogenet. 2005 Apr 15;158(2):119-25 PMID: 15796958
  16. The Fanconi anaemia/BRCA pathway.
    Nat Rev Cancer. 2003 Jan;3(1):23-34 PMID: 12509764
  17. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach.
    Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 PMID: 15224285
  18. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis.
    Cancer Cell. 2003 Jun;3(6):565-76 PMID: 12842085
  19. Fanconi anemia gene mutations in young-onset pancreatic cancer.
    Cancer Res. 2003 May 15;63(10):2585-8 PMID: 12750283
  20. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.
    Cancer Res. 2007 Mar 1;67(5):2187-96 PMID: 17332349
  21. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    J Natl Cancer Inst. 2005 Oct 19;97(20):1507-15 PMID: 16234564
  22. Epidemiology and risk factors for pancreatic cancer.
    Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):197-209 PMID: 16549324
  23. Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion.
    Mod Pathol. 2005 Jul;18(7):959-63 PMID: 15832197
  24. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease.
    Cancer Res. 2006 Jan 15;66(2):1208-17 PMID: 16424060
  25. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent.
    J Pathol. 2003 Sep;201(1):63-74 PMID: 12950018
  26. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets.
    Am J Pathol. 2003 Oct;163(4):1255-60 PMID: 14507635
  27. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas.
    Am J Pathol. 2004 Mar;164(3):903-14 PMID: 14982844
  28. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions.
    Am J Surg Pathol. 2001 May;25(5):579-86 PMID: 11342768
  29. The Hedgehog and Wnt signalling pathways in cancer.
    Nature. 2001 May 17;411(6835):349-54 PMID: 11357142
  30. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds.
    Cancer Res. 2004 Apr 1;64(7):2634-8 PMID: 15059921
  31. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression.
    Cancer Res. 2002 Feb 1;62(3):819-26 PMID: 11830538
  32. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study.
    Clin Gastroenterol Hepatol. 2006 Jun;4(6):766-81; quiz 665 PMID: 16682259
  33. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.
    Am J Pathol. 2000 Jan;156(1):37-43 PMID: 10623651
  34. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
    Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7 PMID: 16857803
  35. Molecular pathogenesis of pancreatic cancer.
    Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):211-26 PMID: 16549325
  36. Epithelial differentiation in pancreatic development and neoplasia: new niches for nestin and Notch.
    J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S78-82 PMID: 15758664
  37. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Oncogene. 1997 Sep;15(11):1283-8 PMID: 9315095
  38. Tissue repair and stem cell renewal in carcinogenesis.
    Nature. 2004 Nov 18;432(7015):324-31 PMID: 15549094
  39. Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression.
    Am J Surg Pathol. 2000 Nov;24(11):1544-8 PMID: 11075857
  40. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features.
    Clin Cancer Res. 1998 Jun;4(6):1527-32 PMID: 9626473
  41. High-resolution characterization of the pancreatic adenocarcinoma genome.
    Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72 PMID: 15199222
  42. Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms.
    Mod Pathol. 2003 Jul;16(7):686-91 PMID: 12861065
  43. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray.
    Mod Pathol. 2003 Sep;16(9):902-12 PMID: 13679454
  44. DNA hypermethylation in tumorigenesis: epigenetics joins genetics.
    Trends Genet. 2000 Apr;16(4):168-74 PMID: 10729832
  45. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms.
    Am J Surg Pathol. 2004 Aug;28(8):977-87 PMID: 15252303
  46. Pancreatic cancer genetic epidemiology consortium.
    Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):704-10 PMID: 16614112
  47. Insulin-promoter-factor 1 is required for pancreas development in mice.
    Nature. 1994 Oct 13;371(6498):606-9 PMID: 7935793
  48. Precursors to invasive pancreatic cancer.
    Adv Anat Pathol. 2005 Mar;12(2):81-91 PMID: 15731576
  49. Prospective identification of tumorigenic breast cancer cells.
    Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 PMID: 12629218
  50. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers.
    Clin Cancer Res. 2004 Apr 1;10(7):2386-92 PMID: 15073115
  51. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.
    Cancer Cell. 2005 May;7(5):469-83 PMID: 15894267
  52. Recent advances in telomere biology: implications for human cancer.
    Curr Opin Oncol. 2004 Jan;16(1):32-8 PMID: 14685090
  53. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis.
    JAMA. 1995 May 24-31;273(20):1605-9 PMID: 7745774
  54. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma.
    Cancer Res. 1997 Jun 1;57(11):2140-3 PMID: 9187111
  55. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.
    Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3636-41 PMID: 8622988
  56. Silencing of microRNAs in vivo with 'antagomirs'.
    Nature. 2005 Dec 1;438(7068):685-9 PMID: 16258535
  57. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma.
    Gastroenterology. 2005 Nov;129(5):1454-63 PMID: 16285947
  58. Functional defects in the fanconi anemia pathway in pancreatic cancer cells.
    Am J Pathol. 2004 Aug;165(2):651-7 PMID: 15277238
  59. Identification and expansion of human colon-cancer-initiating cells.
    Nature. 2007 Jan 4;445(7123):111-5 PMID: 17122771
  60. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer.
    Nat Rev Cancer. 2003 Nov;3(11):807-21 PMID: 14557817
  61. Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice.
    Science. 1987 Oct 9;238(4824):188-93 PMID: 2821617
  62. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?
    Trends Mol Med. 2004 Oct;10(10):481-6 PMID: 15464447
  63. RAS is regulated by the let-7 microRNA family.
    Cell. 2005 Mar 11;120(5):635-47 PMID: 15766527
  64. K-ras mutation and pancreatic adenocarcinoma.
    Int J Pancreatol. 1995 Aug;18(1):1-6 PMID: 7594765
  65. Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers.
    Gastroenterology. 2006 Feb;130(2):548-65 PMID: 16472607
  66. Mesothelin: a new target for immunotherapy.
    Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 PMID: 15217923
  67. Cancer genes and the pathways they control.
    Nat Med. 2004 Aug;10(8):789-99 PMID: 15286780
  68. Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models.
    Clin Cancer Res. 2007 Jan 1;13(1):4-10 PMID: 17200332
  69. Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.
    Cancer Res. 2006 Oct 1;66(19):9722-30 PMID: 17018631
  70. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.
    Nat Med. 1997 Jul;3(7):730-7 PMID: 9212098
  71. Comprehensive proteomic analysis of human pancreatic juice.
    J Proteome Res. 2004 Sep-Oct;3(5):1042-55 PMID: 15473694
  72. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis.
    Am J Pathol. 2001 May;158(5):1677-83 PMID: 11337365
  73. Hedgehog signalling in foregut malignancy.
    Biochem Pharmacol. 2004 Sep 15;68(6):1055-60 PMID: 15313401
  74. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases.
    Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):238-43 PMID: 12966350
  75. A microRNA expression signature of human solid tumors defines cancer gene targets.
    Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 PMID: 16461460
  76. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion.
    Am J Pathol. 2002 Jan;160(1):91-9 PMID: 11786403
  77. Characterization of clonogenic multiple myeloma cells.
    Blood. 2004 Mar 15;103(6):2332-6 PMID: 14630803
  78. LigAmp for sensitive detection of single-nucleotide differences.
    Nat Methods. 2004 Nov;1(2):141-7 PMID: 15782177
  79. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family.
    PLoS Med. 2004 Dec;1(3):e65 PMID: 15630470
  80. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells.
    Cancer. 2006 Jun 1;106(11):2503-13 PMID: 16628653
  81. Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast.
    Cell. 1990 Jun 15;61(6):1121-35 PMID: 1693546
  82. Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma.
    Cancer. 2006 Jul 15;107(2):251-7 PMID: 16752411
  83. Hedgehog signalling in cancer formation and maintenance.
    Nat Rev Cancer. 2003 Dec;3(12):903-11 PMID: 14737121
  84. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.
    Nat Clin Pract Oncol. 2006 Aug;3(8):448-57 PMID: 16894390
  85. Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates.
    Development. 2005 Aug;132(16):3767-76 PMID: 16020518
  86. Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays.
    Oncogene. 2004 Dec 2;23(56):9042-51 PMID: 15489895
  87. Pancreatic carcinoma surveillance in patients with familial melanoma.
    Arch Dermatol. 2003 Aug;139(8):1019-25 PMID: 12925390
  88. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells.
    Cancer Res. 2005 Mar 1;65(5):1619-26 PMID: 15753353
  89. Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers.
    Cancer Biol Ther. 2004 May;3(5):436-40 PMID: 15197345
  90. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.
    Cancer Cell. 2007 Mar;11(3):291-302 PMID: 17349585
  91. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.
    Am J Pathol. 2002 May;160(5):1573-81 PMID: 12000709
  92. Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.
    Mol Cancer Ther. 2005 Dec;4(12):1860-6 PMID: 16373701
  93. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.
    Clin Cancer Res. 2006 Jun 15;12(12):3851-5 PMID: 16778113
  94. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer.
    Neoplasia. 2005 Jun;7(6):556-62 PMID: 16036106
  95. Very high risk of cancer in familial Peutz-Jeghers syndrome.
    Gastroenterology. 2000 Dec;119(6):1447-53 PMID: 11113065
  96. The role of epigenetic alterations in pancreatic cancer.
    J Hepatobiliary Pancreat Surg. 2006;13(4):286-95 PMID: 16858539
  97. Telomerase as a new target for pancreatic cancer treatment.
    J Hepatobiliary Pancreat Surg. 2002;9(3):322-7 PMID: 12353143
  98. miRNAs, cancer, and stem cell division.
    Cell. 2005 Jul 15;122(1):6-7 PMID: 16009126
  99. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas.
    Cancer Cell. 2005 Sep;8(3):185-95 PMID: 16169464
  100. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.
    Cancer Cell. 2007 Mar;11(3):229-43 PMID: 17349581
  101. The paradox of response and survival in cancer therapeutics.
    Blood. 2006 Jan 15;107(2):431-4 PMID: 16150939
  102. MicroRNAs in cell proliferation, cell death, and tumorigenesis.
    Br J Cancer. 2006 Mar 27;94(6):776-80 PMID: 16495913
  103. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.
    Science. 1996 Jan 19;271(5247):350-3 PMID: 8553070
  104. High-throughput oncogene mutation profiling in human cancer.
    Nat Genet. 2007 Mar;39(3):347-51 PMID: 17293865
  105. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.
    Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5947-52 PMID: 16585505
  106. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis.
    Nature. 2003 Oct 23;425(6960):851-6 PMID: 14520413
  107. What's new in pancreatic cancer treatment pipeline?
    Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):315-26 PMID: 16549330
  108. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
    J Clin Oncol. 2004 Apr 15;22(8):1430-8 PMID: 15084616
  109. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).
    Clin Cancer Res. 2001 Dec;7(12):3862-8 PMID: 11751476
  110. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
    Cancer Res. 2003 Dec 15;63(24):8614-22 PMID: 14695172
  111. Genetics and biology of pancreatic ductal adenocarcinoma.
    Genes Dev. 2006 May 15;20(10):1218-49 PMID: 16702400
  112. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression.
    Genes Dev. 2006 Nov 15;20(22):3147-60 PMID: 17114585
  113. Identifying markers for pancreatic cancer by gene expression analysis.
    Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):109-12 PMID: 9488584
  114. Treatment of metastatic pancreatic cancer.
    J Natl Compr Canc Netw. 2005 Sep;3(5):627-36 PMID: 16194454
  115. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity.
    Am J Pathol. 2000 May;156(5):1641-51 PMID: 10793075
  116. Hedgehog/Ras interactions regulate early stages of pancreatic cancer.
    Genes Dev. 2006 Nov 15;20(22):3161-73 PMID: 17114586
  117. MicroRNA expression profiles classify human cancers.
    Nature. 2005 Jun 9;435(7043):834-8 PMID: 15944708
  118. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer.
    Cancer Res. 2006 May 15;66(10):4983-6 PMID: 16707416
  119. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients.
    Nat Genet. 1997 May;16(1):17-8 PMID: 9140390
  120. Alcohol, tobacco and coffee consumption and the risk of pancreatic cancer: results from the Canadian Enhanced Surveillance System case-control project. Canadian Cancer Registries Epidemiology Research Group.
    Eur J Cancer Prev. 2000 Feb;9(1):49-58 PMID: 10777010
  121. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+.
    Am J Pathol. 1998 Jun;152(6):1501-7 PMID: 9626054
  122. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects.
    Semin Radiat Oncol. 2005 Oct;15(4):254-64 PMID: 16183479
  123. Specific expression of an elastase-human growth hormone fusion gene in pancreatic acinar cells of transgenic mice.
    Nature. 1985 Feb 14-20;313(6003):600-2 PMID: 3844051
  124. MicroRNAs linked to pancreatic cancer.
    JAMA. 2007 Mar 7;297(9):937 PMID: 17341695
  125. Dietary and other methyl-group availability factors and pancreatic cancer risk in a cohort of male smokers.
    Am J Epidemiol. 2001 Apr 1;153(7):680-7 PMID: 11282796
  126. Physical activity, obesity, height, and the risk of pancreatic cancer.
    JAMA. 2001 Aug 22-29;286(8):921-9 PMID: 11509056
  127. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.
    Nature. 1994 Feb 17;367(6464):645-8 PMID: 7509044
  128. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma.
    Cancer Res. 2001 Jun 1;61(11):4320-4 PMID: 11389052
  129. Genome-wide aberrations in pancreatic adenocarcinoma.
    Cancer Genet Cytogenet. 2005 Aug;161(1):36-50 PMID: 16080956
  130. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.
    Cold Spring Harb Symp Quant Biol. 2005;70:419-26 PMID: 16869779
  131. Stem cells, cancer, and cancer stem cells.
    Nature. 2001 Nov 1;414(6859):105-11 PMID: 11689955
  132. Point mutations of protein kinases and individualised cancer therapy.
    Expert Opin Pharmacother. 2006 Nov;7(16):2243-61 PMID: 17059381
  133. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.
    Genes Dev. 2006 Nov 15;20(22):3130-46 PMID: 17114584
  134. The concept of synthetic lethality in the context of anticancer therapy.
    Nat Rev Cancer. 2005 Sep;5(9):689-98 PMID: 16110319
  135. Pancreatic cancer in mice and man: the Penn Workshop 2004.
    Cancer Res. 2006 Jan 1;66(1):14-7 PMID: 16397208
  136. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.
    J Exp Med. 2004 Aug 2;200(3):297-306 PMID: 15289501
  137. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells.
    Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4158-63 PMID: 15020770
  138. Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer.
    Nat Med. 2003 Oct;9(10):1266-8 PMID: 12960962
  139. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
    Cancer Res. 1998 Dec 1;58(23):5329-32 PMID: 9850059
  140. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis.
    Cancer Cell. 2005 Jan;7(1):39-49 PMID: 15652748
  141. Mutant KRAS in the initiation of pancreatic cancer.
    Biochim Biophys Acta. 2005 Nov 25;1756(2):97-101 PMID: 16169155
  142. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma.
    Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3254-7 PMID: 11248065
  143. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group.
    J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 PMID: 9091646
  144. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
    J Clin Oncol. 1997 Jun;15(6):2403-13 PMID: 9196156
  145. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.
    Genes Dev. 2003 Dec 15;17(24):3112-26 PMID: 14681207
  146. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer.
    Cancer Res. 2005 Jan 15;65(2):383-6 PMID: 15695377
  147. Real-time detection of mesothelin in pancreatic cancer cell line supernatant using an acoustic wave immunosensor.
    Cancer Detect Prev. 2006;30(2):180-7 PMID: 16647225
  148. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
    Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91 PMID: 15006928
  149. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.
    Nature. 2007 Jan 4;445(7123):106-10 PMID: 17122772
  150. Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs.
    Cancer Biol Ther. 2002 May-Jun;1(3):293-6 PMID: 12432281
  151. BuCy RAFs drive cells into MEK addiction.
    Cancer Cell. 2006 Jan;9(1):9-12 PMID: 16413467
  152. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.
    Cancer Res. 2006 Jan 1;66(1):95-106 PMID: 16397221
  153. Frequent activation of AKT2 kinase in human pancreatic carcinomas.
    J Cell Biochem. 2002;87(4):470-6 PMID: 14735903
  154. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
    Clin Cancer Res. 2005 Oct 15;11(20):7508-15 PMID: 16243825
  155. CDKN2A germline mutations in familial pancreatic cancer.
    Ann Surg. 2002 Dec;236(6):730-7 PMID: 12454511
  156. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia.
    Am J Pathol. 2002 Nov;161(5):1541-7 PMID: 12414502
  157. Dissecting the cellular origins of pancreatic cancer.
    Cell Cycle. 2006 Jan;5(1):43-6 PMID: 16322695
  158. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
    Cancer Res. 1996 Dec 1;56(23):5360-4 PMID: 8968085
  159. Early detection of pancreatic carcinoma.
    Hematol Oncol Clin North Am. 2002 Feb;16(1):37-52 PMID: 12063828
  160. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach.
    Mol Cell Proteomics. 2006 Jan;5(1):157-71 PMID: 16215274
  161. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.
    Curr Biol. 2006 Dec 19;16(24):2385-94 PMID: 17174914
  162. RNAi, microRNAs, and human disease.
    Cancer Chemother Pharmacol. 2006 Nov;58 Suppl 1:s63-8 PMID: 17093929
  163. Brief communication: a new combination in the treatment of advanced pancreatic cancer.
    Semin Oncol. 2005 Dec;32(6 Suppl 8):5-6 PMID: 16360004
  164. Recapitulation of elements of embryonic development in adult mouse pancreatic regeneration.
    Gastroenterology. 2005 Mar;128(3):728-41 PMID: 15765408
  165. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
    JAMA. 2007 Jan 17;297(3):267-77 PMID: 17227978
  166. Identification of pancreatic cancer stem cells.
    Cancer Res. 2007 Feb 1;67(3):1030-7 PMID: 17283135
  167. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.
    Cancer Cell. 2003 Dec;4(6):437-50 PMID: 14706336
  168. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice.
    Cancer Res. 2003 May 1;63(9):2005-9 PMID: 12727809
  169. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Clin Cancer Res. 2006 Jan 15;12(2):442-6 PMID: 16428484
  170. DPC4 gene in various tumor types.
    Cancer Res. 1996 Jun 1;56(11):2527-30 PMID: 8653691
  171. Chromosome instability in cancer: how, when, and why?
    Adv Cancer Res. 2003;87:1-29 PMID: 12641272
  172. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability.
    Cancer Res. 2001 Apr 1;61(7):3139-44 PMID: 11306499
  173. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents.
    Oncogene. 2003 Sep 29;22(42):6598-608 PMID: 14528285
  174. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy.
    Mol Cancer Res. 2005 Jul;3(7):413-23 PMID: 16046552
  175. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study.
    J Natl Cancer Inst. 2002 Sep 4;94(17):1293-300 PMID: 12208894
  176. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.
    Cancer Res. 2000 Apr 1;60(7):2002-6 PMID: 10766191
  177. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).
    Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3598-605 PMID: 14506146
  178. Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis.
    Pancreas. 2007 Jan;34(1):70-9 PMID: 17198186
  179. RAS unplugged: negative feedback and oncogene-induced senescence.
    Cancer Cell. 2006 Dec;10(6):451-3 PMID: 17157783
  180. The bHLH protein PTF1-p48 is essential for the formation of the exocrine and the correct spatial organization of the endocrine pancreas.
    Genes Dev. 1998 Dec 1;12(23):3752-63 PMID: 9851981
  181. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
    Cancer Res. 1997 Aug 1;57(15):3126-30 PMID: 9242437
  182. Ras redux: rethinking how and where Ras acts.
    Curr Opin Genet Dev. 2003 Feb;13(1):6-13 PMID: 12573429
  183. TGF-beta and epithelial-to-mesenchymal transitions.
    Oncogene. 2005 Aug 29;24(37):5764-74 PMID: 16123809
  184. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma.
    Cancer Res. 2003 Jul 15;63(14):4158-66 PMID: 12874021
  185. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape.
    Gastroenterology. 2005 Oct;129(4):1187-97 PMID: 16230073
  186. Differentiating pancreatic lesions by microarray and QPCR analysis of pancreatic juice RNAs.
    Cancer Biol Ther. 2006 Oct;5(10):1383-9 PMID: 17012836
Article Info
Journal
Annual review of pathology
Abbr.
Annu Rev Pathol
ISSN
1553-4006
DOI
10.1146/annurev.pathmechdis.3.121806.154305
Email
amaitra1@jhmi.edu
Published
2008-00-00
Pages
157-88
Language
English
Region
United States
NLM ID
101275111
PMCID
PMC2666336
Subset
IM
Grants
NCI NIH HHS · R01 CA113669-01 · United States
NCI NIH HHS · P50 CA062924 · United States
NCI NIH HHS · R01 CA113669-04 · United States
NCI NIH HHS · R01CA113669 · United States
NCI NIH HHS · R01 CA113669-02 · United States
NCI NIH HHS · P50 CA062924-150016 · United States
NCI NIH HHS · P50CA062924 · United States
NCI NIH HHS · R01 CA113669-03 · United States
NCI NIH HHS · R01 CA113669 · United States
NCI NIH HHS · R01 CA113669-05 · United States
NCI NIH HHS · P50 CA062924-140016 · United States
External Links
PubMed source DOI: 10.1146/annurev.pathmechdis.3.121806.154305 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2